Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 0.56 |
| ▸ | JAK3 | P52333 | 20/20 | 0.56 |
| ▸ | JAK2 | O60674 | 15/20 | 0.56 |
| ▸ | JAK1 | P23458 | 15/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19469211 | 1.00 | TYK2 (0.56) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL29565537 | 1.00 | TYK2 (0.56) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL29707880 | 1.00 | TYK2 (0.56) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL19469215 | 0.97 | JAK3 (0.59) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL19469214 | 0.97 | JAK3 (0.59) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL29565830 | 0.97 | JAK3 (0.59) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL30930692 | 0.97 | JAK3 (0.59) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL18260560 | 0.95 | TYK2 (0.54) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL18260557 | 0.95 | TYK2 (0.54) | TYK2JAK3JAK2JAK1P2RX3 | |
| SCHEMBL21569472 | 0.93 | JAK3 (0.58) | TYK2JAK3JAK2JAK1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10072026-B2 | Crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170305934-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305934-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | JAK1, JAK2, JAK3 | TYK2 6/4885JAK3 3/4885JAK2 2/4885 |
| US-10072026-B2 | Crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | JAK1, JAK3, MAP3K1 | TYK2 38/4885JAK3 2/4885JAK2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.